Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Revenue: 2022-2025

Historic Revenue for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$403.4 million.

  • Addex Therapeutics' Revenue fell 316559.06% to -$403.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$437.7 million, marking a year-over-year decrease of 46714.72%. This contributed to the annual value of $459,343 for FY2024, which is 74.42% down from last year.
  • Per Addex Therapeutics' latest filing, its Revenue stood at -$403.4 million for Q2 2025, which was down 1,073.37% from -$34.4 million recorded in Q1 2025.
  • Addex Therapeutics' 5-year Revenue high stood at $701,646 for Q2 2023, and its period low was -$403.4 million during Q2 2025.
  • Moreover, its 3-year median value for Revenue was $150,233 (2024), whereas its average is -$43.6 million.
  • As far as peak fluctuations go, Addex Therapeutics' Revenue skyrocketed by 268.56% in 2023, and later plummeted by 316,559.06% in 2025.
  • Over the past 4 years, Addex Therapeutics' Revenue (Quarterly) stood at $614,955 in 2022, then tumbled by 71.87% to $172,994 in 2023, then slumped by 99.00% to $1,721 in 2024, then slumped by 316,559.06% to -$403.4 million in 2025.
  • Its last three reported values are -$403.4 million in Q2 2025, -$34.4 million for Q1 2025, and $1,721 during Q4 2024.